Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug DevelopmentGlobeNewsWire · 2 days ago
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · 2 days ago
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical TrialsGlobeNewsWire · 5 days ago
3 Top Small-Cap Stocks With Market-Beating MomentumSeeking Alpha · Oct 15, 2026
MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head ContrastDefense World · Oct 9, 2026
Ausbil Investment Management Ltd Decreases Stake in Fortrea Holdings Inc. $FTREDefense World · Oct 8, 2026Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | $0.18 | $0.23 | Beat |
| May 5, 2026 | $0.03 | $0.16 | Beat |
| Feb 26, 2026 | $0.16 | $0.09 | Miss |
| Nov 5, 2025 | $0.16 | $0.12 | Miss |
| Aug 6, 2025 | $0.06 | $0.19 | Beat |
| May 12, 2025 | -$0.07 | $0.02 | Beat |